^
Association details:
| Biomarker: | P2RY8-CRLF2 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | JQ-1 (BET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia
Excerpt:
...mice were engrafted with a primary B-ALL sample that harbors a P2RY8-CRLF2 rearrangement...After 4 weeks of treatment, mice receiving JQ1 had lower white blood cell and higher platelet counts compared with vehicle-treated mice (Figure 5D), consistent with reduced leukemic burden in the peripheral blood and bone marrow.
DOI:
https://dx.doi.org/10.1182%2Fblood-2012-02-413021
